

Jorg Oddens

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5305378/jorg-oddens-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38

papers

2,166

citations

16

h-index

42

g-index

42

ext. papers

2,710

ext. citations

6.6

avg, IF

4.07

L-index

#	Paper	IF	Citations
38	Duration of androgen suppression in the treatment of prostate cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 2516-27	59.2	686
37	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guërin. <i>European Urology</i> , 2016 , 69, 60-9	10.2	284
36	Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guërin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. <i>European Urology</i> , 2013 , 64, 166-74	10.2	270
35	Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? <i>European Urology</i> , 2015 , 68, 221-31	10.2	184
34	Side effects of Bacillus Calmette-Guërin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance. <i>European Urology</i> , 2014 , 66, 16-21	10.2	170
33	Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. <i>Investigative Radiology</i> , 2014 , 49, 165-72	10.1	79
32	One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. <i>European Urology</i> , 2004 , 46, 336-8	10.2	78
31	Holmium laser lithotripsy for ureteral calculi: predictive factors for complications and success. <i>Journal of Endourology</i> , 2008 , 22, 257-60	2.7	61
30	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
29	Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer. <i>Investigative Radiology</i> , 2013 , 48, 152-7	10.1	58
28	The effect of age on the efficacy of maintenance bacillus Calmette-Guërin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. <i>European Urology</i> , 2014 , 66, 694-701	10.2	48
27	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019 , 30, 1697-1727	10.3	28
26	Cancer survivors' preference for follow-up care providers: a cross-sectional study from the population-based PROFILES-registry. <i>Acta Oncologica</i> , 2017 , 56, 278-287	3.2	25
25	Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guërin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. <i>BMC International</i> , 2016 , 118, 423-8	5.6	21
24	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019 , 5, 407-415	5.1	19
23	Prostate-sparing cystectomy: long-term oncological results. <i>BJU International</i> , 2009 , 104, 1239-43	5.6	17
22	External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. <i>European Urology</i> , 2009 , 56, 113-21	10.2	16

21	Non-operative treatment for perforated gastro-duodenal peptic ulcer in Duchenne muscular dystrophy: a case report. <i>BMC Surgery</i> , 2004 , 4, 1	2.3	9
20	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019 , 19, 1133	4.8	9
19	Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study. <i>BMC Cancer</i> , 2018 , 18, 861	4.8	9
18	Reply to Stephen B. Williams and Ashish M. Kamat Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus	10.2	8
17	Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study. <i>JMIR Research Protocols</i> , 2020 , 9, e15687	2	6
16	Deep Learning-based Recurrence Prediction in Patients with Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2020 ,	5.1	4
15	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guërin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020 , 203, 283-291	2.5	3
14	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review.. <i>Cancers</i> , 2021 , 14,	6.6	3
13	The challenge of prostate biopsy guidance in the era of mpMRI detected lesion: ultrasound-guided versus in-bore biopsy. <i>British Journal of Radiology</i> , 2021 , 20210363	3.4	2
12	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. <i>BJU International</i> , 2021 , 128, 511-518	5.6	1
11	Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.. <i>BJU International</i> , 2022 ,	5.6	1
10	Type of treatment, symptoms and patient satisfaction play an important role in primary care contact during prostate cancer follow-up: results from the population-based PROFILES registry. <i>BMC Family Practice</i> , 2021 , 22, 218	2.6	0
9	Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.. <i>Therapeutic Advances in Urology</i> , 2022 , 14, 17562872221088536	3.2	0
8	The effect of metformin on bladder cancer incidence and outcomes – systematic review and meta-analysis. <i>Bladder Cancer</i> , 2022 , 1-18	1	0
7	A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.. <i>Scientific Reports</i> , 2022 , 12, 7017	4.9	0
6	De behandeling van blaaskanker vraagt om gecentraliseerde zorg. <i>Tijdschrift Voor Urologie</i> , 2017 , 7, 162-166		
5	Case report. Endo-ureterale ballonkatheter bij urinelekkage en ureterstricturen na urinedeviatie volgens Bricker. <i>Tijdschrift Voor Urologie</i> , 2017 , 7, 23-26	0.2	
4	Rare cause of ureteral stenosis more than 10 years after kidney transplantation. <i>Urology</i> , 2005 , 65, 798	1.6	

- 3 Recurrence in Non-Muscle Invasive Bladder Cancer Patients: External Validation of the EORTC, CUETO and EAU Risk Tables and Towards a Non-Linear Survival Model. *Bladder Cancer*, **2020**, 6, 277-284 ¹
- 2 A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.. *European Urology Open Science*, **2022**, 39, 7-13 0.9
- 1 Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study.. *European Urology Open Science*, **2022**, 39, 48-54 0.9